Siltuximab for side effects after CAR-T in multiple myeloma
Treatments studied
Part of Cancer clinical trials.
This trial tests if the drug Siltuximab can help control side effects (CRS and ICANS) that sometimes happen after CAR-T treatment for multiple myeloma. It may help patients who develop these symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have multiple myeloma.
- You must have had CAR-T treatment and developed CRS (fever, low blood pressure) or ICANS (confusion, trouble speaking) at any level (grade 1 or higher).
- Your kidneys (creatinine clearance) must be 30 mL/min or higher.
- You cannot have severe heart, liver, or lung problems, active infections, or low blood counts (platelets, white cells, or red cells).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy (CAR-T cells) for people with multiple myeloma who also have kidney problems. It aims to see if this treatment can help keep the cancer in remission after initial therapy.
This trial is testing a new immunotherapy treatment using CAR-T cells for people with newly diagnosed multiple myeloma who cannot have a stem cell transplant. The treatment aims to target and destroy myeloma cells that have BCMA and GPRC5D proteins on their surface.
This trial tests if siltuximab can prevent severe immune-related side effects when patients restart immunotherapy (anti-PD-1/PD-L1) after previous severe side effects. It aims to make rechallenge safer for people with advanced cancer.
This study looks at late side effects that may happen after CAR-T therapy (cilta-cel) for multiple myeloma. It aims to better understand these delayed toxicities so doctors can manage them more effectively.
This trial tests a new CAR-T cell treatment (IASO104) for people with multiple myeloma that has come back or not responded to at least three prior treatments. It aims to see if this therapy can help control the disease with manageable side effects.
This trial tests whether adding two drugs, dasatinib and quercetin, to CAR-T therapy can help people with multiple myeloma that has come back or not responded to past treatments. It aims to make the CAR-T cells work better and reduce side effects.
Hear when a new Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.